Effect of Digoxin on the Color Vision Disorder, A Case-Control Study


Digoxin toxicity, color vision disorder, case-control study.

How to Cite

Toba Kazemi, Mohammad Hossien Davari, & Hanie Afrazande. (2021). Effect of Digoxin on the Color Vision Disorder, A Case-Control Study. Journal of Basic & Applied Sciences, 9, 479–482. https://doi.org/10.6000/1927-5129.2013.09.61


Background and Aim: Digoxin is a drug commonly used in order to treat cardiac failure but its use has got different complications including color vision disorder .Regarding the high prevalence of cardiac failure and the role of taking this drug by patients, it was decided to study color vision disorder in patients who take digoxin.

Materials and Methods: The present case-control study was conducted during 2008-2009 in Valli-e-asr hospital in Birjand.The case group consisted of 59 patients having cardiac failure who, at least, had taken oral digoxin for one year. The controls were non-cardiac patients referring to the hospital or were patients’ attendants who did not take digoxin. The controls were matched with the cases with respect to age and sex. Both groups were examined regarding whether they had color vision disorder or not by means of Ishiharatest. Venous blood was derived from all the cases to assess serum digoxin level.

Then, the obtained data was an encoded and statistically analysed by means of SPSS software at the significant level α=0.05.

Findings:In this survey, 59 patients with Heart failure who took digoxin and 59 controls were studied. Relative frequency of color vision disorder in the cases was estimated at 6.8%, but in the controls it was estimated at 1.7%; hence the difference was not statistically significant (P=0.36).Frequency of color vision disorder did not reveal a significant difference regarding age and sex. Serum digoxin level was abnormal in 5.1% of the patients. A significant difference was not found between mean serum digoxin and color vision disorder.

Results:Using color vision disorder, as a diagnostic measure of Digoxin toxicity, is of no use.



Kazemi T, Sharifzadeh G, Zarban A, Fesharakinia A. Comparison of components of metabolic syndrome in premature myocardial infarction in an Iranian population: a case -control study. Int J Prev Med 2013; 4(1): 110-4. PMID: 23411742

The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33. http://dx.doi.org/10.1056/NEJM199702203360801

Orrico KB, Wu M, Wilson AR. Assessment of the appropriateness of serum digoxin concentration measurement in a medical group setting. J Manag Care Pharm 2011; 17: 695-700.

Ashraf A. Digoxin intoxication. Shiraz E Med J 2002; 3: 3.

Goldstein RL, Stanton BA, Lipson MJ. Clinical utility of serum digoxin level tests in hospitalized elderly patients. Arch Phys Med Rehabil 1986; 67: 34-7.

Honrubia A, Andrés JM, Alcaine F, Bonasa E, Fernández J, Luján B. Visual disorders induced by therapeutic levels of digoxin. Arch Soc Esp Oftalmol 2000; 75: 55-6.

Madreperla SA, Johnson MA, Nakatani K. Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol 1994; 112: 807-12. http://dx.doi.org/10.1001/archopht.1994.01090180105044

Wolin MJ. Digoxin visual toxicity with therapeutic blood levels of digoxin. Am J Ophthalmol 1998; 125: 406-7. http://dx.doi.org/10.1016/S0002-9394(99)80161-5

Weleber RG, Shults WT. Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch Ophthalmol 1981; 99: 1568-72. http://dx.doi.org/10.1001/archopht.1981.03930020442007

Butler VP Jr, Odel JG, Rath E, Wolin MJ, Behrens MM, Martin TJ, et al. Digitalis-induced visual disturbances with therapeutic serum digitalis concentrations. 1995 Ann Intern Med 1995; 123: 676-80. http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00006

Lawrenson JG, Kelly C, Lawrenson AL, Birch J. Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br J Ophthalmol 2002; 86: 1259-61. http://dx.doi.org/10.1136/bjo.86.11.1259

Shoja MR, Falah Tafti MR. Effect of digoxin on acquired color vision defects. Iranian J Ophthalmol 2005; 18: 9-15.

Duncker G, Horst H, Kolenda KD, Schenck F. Color perception disorders in therapeutic glycoside serum concentrations. Fortschr Med 1983; 101: 1970-3.

Aronson JK, Ford AR. The use of colour vision measurement in the diagnosis of digoxin toxicity. Q J Med 1980; 49: 273-82.

Joubert PH, Venter CP, du Plooy WJ. A comparison of the effects of digoxin and digitoxin on systolic time intervals and colour vision. Eur J Clin Pharmacol 1991; 40: 221-3. http://dx.doi.org/10.1007/BF00315199

Konstantakopoulou E, Rodriguez-Carmona M, Barbur JL. Processing of color signals in female carriers of color vision deficiency. J Vis 2012; 12: 2. http://dx.doi.org/10.1167/12.2.11

Shokooh AR, Soleimani MR, Zarei R. Relative prevalence of color vision deficiency among Iranian female high school students. Intl J Ophthalmol 2009; 9: 1237-8.

Heravian J, Shoeibi N, Azimi A, et al. Evaluation of contrast sensitivity, color vision and visual acuity in patients with and without diabetes. Iranian J Ophthal 2010; 22: 33-40

Attarchi MS, Labbafinejad Y, Mohammadi S. Occupational exposure to different levels of mixed organic solvents and color vision impairment. Neurotoxicol Teratol 2010; 32: 558-62. http://dx.doi.org/10.1016/j.ntt.2010.05.003

Dargahi H, Einollahi N, Dashti N. Color blindness defect and medical laboratory technologists: unnoticed problems and the care for screening. Acta Med Iran 2010; 48: 172-7.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.